In short
This article provides an overview of a clinical trial investigating the use of VTX-801, a gene therapy drug containing an Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human ATP7B, for the treatment of Wilson's Disease. The trial aims to assess the safety, tolerability, and potential effectiveness of this innovative approach in adult patients with Wilson's Disease.
At a glance
- Study Type
- Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design
- Drug Name
- VTX-801 (Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human ATP7B)
- Condition
- Wilson's Disease
- Primary Objective
- Assess safety and tolerability of single ascending doses of VTX-801
- Secondary Objectives
- Explore pharmacodynamics and efficacy, assess immune responses, support dose selection
- Key Inclusion Criteria
- Adults 18-65 years, confirmed Wilson's Disease diagnosis, stable for ≥1 year
- Key Exclusion Criteria
- Liver cirrhosis, HIV, hepatitis B/C, severe renal impairment, pregnancy
- Administration
- Single intravenous dose
- Follow-up Duration
- 5 years
What is VTX-801?
VTX-801 is a new gene therapy medication being developed to treat Wilson's Disease. It is currently being tested in a Phase I/II clinical trial to assess its safety and effectiveness in adult patients.
The full name of this medication is ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 3B ENCODING SHORTENED HUMAN ATP7B. This long name describes how the medication is made and how it works. Let's break it down:
- Adeno-associated viral vector: This is a harmless virus that has been modified to carry genetic material into cells.
- Serotype 3B: This refers to a specific type of the virus that has been chosen for this therapy.
- Encoding shortened human ATP7B: The virus carries a shortened version of the ATP7B gene, which is the gene that doesn't work properly in people with Wilson's Disease.
Wilson's Disease
Wilson's Disease is a rare genetic disorder that causes copper to build up in the body, particularly in the liver and brain. This can lead to serious health problems if left untreated. Currently, patients with Wilson's Disease need to take medication daily for their entire lives to manage the condition.
How VTX-801 Works
VTX-801 is a type of gene therapy. It works by delivering a working copy of the ATP7B gene to the patient's liver cells. This gene helps the body remove excess copper properly. The therapy uses a modified virus to carry the gene into the cells.
Specifically, VTX-801 contains:
- A non-replicating recombinant adeno-associated viral (AAV) vector: This is the modified virus that carries the gene.
- A shortened form of the human ATP7B gene (ATP7B-minigene): This is a compact version of the gene that still functions properly.
- Instructions for making a shortened but functional form of the ATP7B protein (miniATP7B): This protein helps remove excess copper from the body.
The therapy is given as a single dose through an intravenous (IV) infusion, which means it's delivered directly into the bloodstream.
Clinical Trial Details
The clinical trial for VTX-801 is a Phase I/II study, which means it's an early-stage trial focused on safety and initial effectiveness. Here are some key details about the trial:
- It's a multicenter trial, meaning it's being conducted at multiple hospitals or research centers.
- It's non-randomized and open-label, which means all participants receive the treatment and both patients and doctors know what treatment is being given.
- The trial uses an adaptive design, allowing for modifications based on early results.
- Patients will be followed for 5 years after receiving the treatment.
- The trial uses a single dose-escalation approach, meaning different groups of patients may receive different doses of the medication to find the best dose.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some of the key inclusion criteria are:
- Age between 18 and 65 years old
- Confirmed diagnosis of Wilson's Disease
- Currently receiving treatment for Wilson's Disease according to international recommendations
- Stable Wilson's Disease for at least 1 year
There are also several exclusion criteria, which are conditions that would prevent a person from participating in the trial. These include certain liver problems, other health conditions, and pregnancy.
Safety and Effectiveness
The main goal of this trial is to assess the safety and tolerability of VTX-801. Researchers will be looking at:
- Side effects that occur during treatment
- Changes in laboratory test results
- Changes in vital signs and heart activity (ECG)
- Changes in brain and abdominal MRI scans
The trial will also look at how well the treatment works. This includes measuring:
- Copper levels in urine over 24 hours
- Activity of a protein called ceruloplasmin in the blood
- Whether patients respond to the treatment
- How the immune system responds to the treatment
It's important to note that as this is an early-stage trial, the full effectiveness and any potential long-term side effects of VTX-801 are not yet known. More research will be needed to fully understand how well this treatment works and how safe it is for long-term use.